Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M46,639Revenue $M2,820Net Margin (%)12.3Z-Score23.0
Enterprise Value $M46,197EPS $3.1Operating Margin %29.7F-Score5
P/E(ttm))148Cash Flow Per Share $-2.0Pre-tax Margin (%)27.5Higher ROA y-yN
Price/Book18.210-y EBITDA Growth Rate %0Quick Ratio3.1Cash flow > EarningsY
Price/Sales18.45-y EBITDA Growth Rate %0Current Ratio3.3Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %2.8ROA % (ttm)10.1Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)2ROE % (ttm)15.0Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M103ROI % (ttm)53.3Gross Margin Increase y-yY

Gurus Latest Trades with REGN

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
REGNVanguard Health Care Fund 2014-12-31 Add0.12%$328.07 - $434.95
($393.59)
$ 454.5013%Add 4.49%2,921,000
REGNRay Dalio 2014-12-31 Add0.03%$328.07 - $434.95
($393.59)
$ 454.5013%Add 637.50%11,800
REGNAndreas Halvorsen 2014-12-31 Sold Out -1.6%$328.07 - $434.95
($394.04)
$ 454.5013%Sold Out0
REGNJoel Greenblatt 2014-12-31 Sold Out -0.01%$328.07 - $434.95
($394.04)
$ 454.5013%Sold Out0
REGNAndreas Halvorsen 2014-09-30 Reduce-2.35%$296.41 - $364.41
($335.27)
$ 454.5026%Reduce -63.53%1,080,682
REGNRay Dalio 2014-09-30 Reduce-0.04%$296.41 - $364.41
($335.27)
$ 454.5026%Reduce -91.30%1,600
REGNAndreas Halvorsen 2014-06-30 Add2.39%$277.29 - $313.74
($296.6)
$ 454.5035%Add 181.75%2,963,456
REGNVanguard Health Care Fund 2014-06-30 Add0.79%$277.29 - $313.74
($296.6)
$ 454.5035%Add 60.34%2,795,500
REGNFrank Sands 2014-06-30 Add0.64%$277.29 - $313.74
($296.6)
$ 454.5035%Add 22.32%4,907,362
REGNRay Dalio 2014-06-30 Buy 0.04%$277.29 - $313.74
($296.6)
$ 454.5035%New holding18,400
REGNAndreas Halvorsen 2014-03-31 Buy 1.3%$267.62 - $347.62
($307.2)
$ 454.5032%New holding1,051,800
REGNVanguard Health Care Fund 2014-03-31 Add0.29%$267.62 - $347.62
($306.26)
$ 454.5033%Add 23.47%1,743,468
REGNFrank Sands 2014-03-31 Add0.22%$267.62 - $347.62
($307.2)
$ 454.5032%Add 7.48%4,012,062
REGNRon Baron 2014-03-31 Buy 0.01%$267.62 - $347.62
($307.2)
$ 454.5032%New holding6,084
REGNJoel Greenblatt 2013-12-31 Sold Out -0.03%$261.88 - $313.67
($287.35)
$ 454.5037%Sold Out0
REGNFrank Sands 2013-09-30 Add0.56%$227.65 - $309.174
($262.76)
$ 454.5042%Add 20.34%3,777,357
REGNJoel Greenblatt 2013-09-30 Buy 0.03%$227.65 - $309.174
($262.76)
$ 454.5042%New holding3,285
REGNRay Dalio 2013-09-30 Sold Out -0.01%$227.65 - $309.174
($262.76)
$ 454.5042%Sold Out0
REGNFrank Sands 2013-06-30 Add1.07%$178.51 - $282.8
($232.86)
$ 454.5049%Add 81.03%3,138,793
REGNRay Dalio 2013-06-30 Buy 0.01%$178.51 - $282.8
($232.86)
$ 454.5049%New holding4,100
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

REGN is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


REGN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BAKER CHARLES ADirector 2015-03-25Sell5,000$454.96-0.1view
Aberman Michael SSVP Strategy Investor Relation 2015-03-24Sell4,843$478.99-5.11view
Aberman Michael SSVP Strategy Investor Relation 2015-03-18Sell3,442$465-2.26view
Terifay Robert JSVP Commercial 2015-03-17Sell10,993$451.010.77view
LAROSA JOSEPH JSVP General Counsel and Secret 2015-03-16Sell18,311$4501view
McCorkle Douglas SVP Controller and Asst Treasur 2015-02-27Sell3,000$416.249.19view
Tessier-Lavigne MarcDirector 2015-02-26Sell3,000$421.957.71view
Terifay Robert JSVP Commercial 2015-02-24Sell11,173$423.677.28view
Aberman Michael SSVP Strategy Investor Relation 2015-02-24Sell3,374$418.488.61view
Van Plew Daniel PSVP & General Mgr Industrial O 2015-02-23Sell9,431$427.826.24view

Press Releases about REGN :

    Quarterly/Annual Reports about REGN:

    News about REGN:

    Articles On GuruFocus.com
    Brean Capital Weighs in on Medivation Following Update on TERRAIN Study Mar 26 2015 
    1 Feb 23 2015 
    1 Feb 23 2015 
    Can These Three BioTech Companies Make It Big? Feb 20 2015 
    J.P. Morgan Chimes In With Ratings On BioTech Stocks Jan 06 2015 
    Weekly Insider Sells Highlight: REGN, HSP, TYC, AAPL Nov 30 2014 
    S&P 500 Finishes Above 2,000 Aug 27 2014 
    How Sanofi's Growth Strategy Will Catapult Afrezza Into a Blockbuster Drug Aug 20 2014 
    Weekly Insider Sells Highlight: MSFT, REGN, ATVI, MAA Feb 17 2014 
    Insiders Are Buying Ophthotech Oct 08 2013 


    More From Other Websites
    Cramer Remix: A bottom in biotech? Hardly Mar 27 2015
    Cramer: 4 horsemen of biotech & semis are back Mar 27 2015
    Stocks Finish Lower for the Week as Fed Talk Spooks Investors Mar 27 2015
    11 promising drugs poised to be the next billion-dollar blockbusters Mar 27 2015
    Regeneron's Eylea Gets FDA Approval for Label Expansion - Analyst Blog Mar 26 2015
    Biotech Battering Renews Bubble Debate Over Sector's Pricey Stocks Mar 26 2015
    Dow tumbles 292 points as economy shows cracks Mar 25 2015
    In A Genetic Portrait Of A Nation, A Map Of The Future Mar 25 2015
    Biotechs On Track For Worst Week In A Year Mar 25 2015
    EYLEA® (aflibercept) Injection Receives FDA Approval for the Treatment of Diabetic Retinopathy in... Mar 25 2015
    EYLEA® (aflibercept) Injection Receives FDA Approval for the Treatment of Diabetic Retinopathy in... Mar 25 2015
    Lightning Round: Problem with Visa's split Mar 24 2015
    Bristol, Sanofi and Novartis drugs to shine among 2015 launches Mar 23 2015
    Bristol, Sanofi and Novartis drugs to shine among 2015 launches Mar 23 2015
    Actavis' Wide-Moat Transformation Offers Shareholder Rewards Mar 23 2015
    REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... Mar 23 2015
    Bristol, Sanofi and Novartis drugs to shine among 2015 launches Mar 22 2015
    Don't-Buy Call on Biotech; Oil Pipeline: Jim Cramer's Best Blogs Mar 21 2015
    Cramer Remix: Cha-ching! Time to cash in Mar 20 2015
    Cramer's don't buy call: REGN & BIIB Mar 20 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK